Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance

This article was originally published in The Gray Sheet

  • News

Executive Summary

FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency

You may also be interested in...



DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.

Device Firms Want Their Own Guidelines On Risk Information In Ads

FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed

Device Firms Want Their Own Guidelines On Risk Information In Ads

FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

Theradaptive Receives $7.4M From DoD, Advances Human Trials With ‘Paint-Like’ Regenerative Therapeutic

Minute Insight: Virtual Incision Draws In Another $30m With Its Table-Top Surgical Robot

Generating And Assessing Evidence To Optimize MDR And IVDR Governance and Innovation

See All
UsernamePublicRestriction

Register

MT027499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By